Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements
Authors:
- Mislav Barisic-JamanMBMislav Barisic-Jaman
- Marko MilosevicMMMarko Milosevic
- Viktoria SkurlaVSViktoria Skurla
- David DohoczkyDDDavid Dohoczky
- Josip StojicJSJosip Stojic
- Petra Dinjar KujundzicPKPetra Dinjar Kujundzic
- Maja Cigrovski BerkovicMaja Cigrovski Berkovic
- Ana Majic-TenggAMAna Majic-Tengg
- Ana MatijacaAMAna Matijaca
- Tomo LucijanicTLTomo Lucijanic
- Mirjana Kardum-PejicMKMirjana Kardum-Pejic
- Vlatka Pandzic JaksicVJVlatka Pandzic Jaksic
Open Access
- 30 January 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (2) , 323
Abstract
Patients with type 2 diabetes (T2D) are at risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated the prevalence of compensated advanced chronic liver disease (cACLD) and steatosis in patients with T2D using the new non-invasive diagnostic methods of shear wave measurements (SWMs) and attenuation (ATT) measurements in comparison with those of vibration-controlled transient elastography (VCTE) and the controlled attenuation parameter (CAP), which served as the reference methods. Among 214 T2D patients, steatosis at any grade and cACLD were revealed in 134 (62.6%) and 19 (8.9%) patients, respectively. SWMs showed a high correlation with VCTE (Spearman’s ρ = 0.641), whereas SWMs produced lower (mean of −0.7 kPa) liver stiffness measurements (LSMs) overall. At a LSM of >11.0 kPa (Youden), SWMs had an AUROC of 0.951 that was used to diagnose cACLD (defined as a LSM of >15 kPa through VCTE) with 84.2% sensitivity and 96.4% specificity. The performance of ATT measurements in diagnosing liver steatosis at any grade (defined as the CAP of ≥274 dB/m) was suboptimal (AUROC of 0.744 at the ATT measurement cut-off of >0.63 dB/cm/MHz (Youden) with 59% sensitivity and 81.2% specificity). In conclusion, the prevalence of liver steatosis and previously unrecognized cACLD in patients with T2D is high and SWMs appear to be a reliable diagnostic method for this purpose, whereas further investigation is needed to optimize the diagnostic performance of ATT measurements.Keywords
This publication has 41 references indexed in Scilit:
- Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisWorld Journal of Gastroenterology, 2014
- The global NAFLD epidemicNature Reviews Gastroenterology & Hepatology, 2013
- Feasibility and Diagnostic Performance of the Fibroscan XL Probe for Liver Stiffness Measurement in Overweight and Obese PatientsHepatology, 2011
- Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)Journal of Hepatology, 2010
- Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort StudyAmerican Journal of Gastroenterology, 2010
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- Microvascular and Macrovascular Complications of DiabetesClinical Diabetes, 2008
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Global and societal implications of the diabetes epidemicNature, 2001